Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TARO WILL BEGIN SHIPPING FIRST GENERIC VERSION OF TOPICORT

Executive Summary

TARO WILL BEGIN SHIPPING FIRST GENERIC VERSION OF TOPICORT (desoximetasone) by Jan. 15, the generic firm said. Taro Pharmaceuticals' desoximetasone 0.05% and 0.25% cream was approved by FDA on Nov. 30. The topical corticosteroid will be "AB-rated" (therapeutically equivalent) to the brandname product, Hoechst-Roussel's Topicort, FDA indicated. Taro's desoximetasone will be available at a price to wholesalers of $6.05 for the 0.25% cream in a 15 gm tube and$14.69 for a 60 gm tube. The price to wholesalers for the 0.05% cream will be $4.60 for a 15 gm tube and $11.19 for a 60 gm tube. Taro said that its product will be 20% less than the brandname product's average wholesale price. The company plans to run an ad announcing the availability of the product in the January issues of Drug Topics and Drug Store News. Mailings will also be sent out to wholesalers and chain drug stores. Taro filed its ANDA for desoximetasone cream in March 1989. To gain approval, the drug underwent vasoconstrictor tests, a standard equivalence test for generic nonsystemically absorbed drugs. The corticosteroid is used for dermatological ailments. The labeling for Topicort states that it is indicated for "the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses." Taro Pharmaceuticals, U.S.A., headquartered in Hawthorne, N.Y., is the U.S. subsidiary of Taro-Vit, an Israel-based company. In 1984, Taro gained the first generic approval of another topical corticosteroid, fluocinonide (Syntex' Lidex).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel